Prostate cancer is a diseases that affects a significant portion of men, with the chance of getting prostate cancer getting higher as men getting older. It has been recommended that older men go in for regular medical tests to make sure that they are not at early stages of prostate cancer. In a recent drug trial, men who had an increased risk of developing prostate cancer were administered the drug, and it was found to be effective in some cases (link to article):
A novel herb-based therapeutic called Zyflamend has been found to be linked with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer in its phase I clinical trial.
"Since we know that men with HGPIN have an increased risk for developing prostate cancer, new strategies formulated to decrease cancer risk, prevent or delay surgery, and improve quality of life, will be greatly beneficial for these men," said senior author of the study Dr. Aaron E. Katz, an associate professor of Urology at Columbia University College of Physicians and Surgeons. The researchers say that basic science studies have suggested that Zyflamend may have an anti-inflammatory mechanism of action, and the agent has been found to be effective in decreasing the proliferation of prostate cancer
in cell culture.
No comments:
Post a Comment